Related Experiment Videos
Continuous and intermittent levamisole. A controlled trial
Annals of the Rheumatic Diseases
|June 1, 1978
Abstract:
A double-blind comparative trial showed that intermittent levamisole therapy (150 mg daily for 3 days of each week) was as effective as continuous therapy (150 mg daily) in rheumatoid arthritis and with slightly fewer side effects.
Insights
Intermittent levamisole therapy is as effective as continuous therapy for rheumatoid arthritis. This dosing schedule also resulted in fewer side effects, offering a potentially improved treatment option.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- Levamisole is an immunomodulatory agent used in RA treatment.
- Continuous dosing regimens are common, but side effects can occur.
Purpose of the Study:
- To compare the efficacy and safety of intermittent levamisole therapy versus continuous levamisole therapy in patients with rheumatoid arthritis.
Main Methods:
- A double-blind, comparative clinical trial was conducted.
- Patients received either intermittent levamisole (150 mg daily for 3 days/week) or continuous levamisole (150 mg daily).
- Efficacy and side effect profiles were assessed.
Main Results:
- Intermittent levamisole therapy demonstrated comparable efficacy to continuous therapy in treating rheumatoid arthritis.
- The intermittent regimen was associated with slightly fewer adverse side effects compared to the continuous regimen.
Conclusions:
- Intermittent levamisole therapy presents a viable and potentially safer alternative for rheumatoid arthritis management.
- This dosing strategy may improve patient tolerability without compromising therapeutic benefits.